Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (211-220 of 578) with videos related to

Pageof 58
Sort By:
Anticancer Research|December 11, 2013
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trialAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
Pharmaceutics|April 23, 2022
Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse ModelRoxanne Wouters, Sara Westrøm, Ann Vankerckhoven, et al.
Cancers|March 28, 2024
TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing MiceYani Berckmans, Ann Vankerckhoven, Aarushi Audhut Caro, et al.
Gynecologic Oncology|June 24, 2005
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancerFrederic Amant, Isabelle Cadron, Luca Fuso, et al.
Gynecologic Oncology|January 31, 2013
A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal massJeroen Kaijser, Toon Van Gorp, Kirsten Van Hoorde, et al.
Gynecologic Oncology|May 1, 2015
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancerScott McMeekin, Don Dizon, James Barter, et al.
Anticancer Research|October 30, 2016
The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian CancerEva Vindevogel, Thaïs Baert, Anaïs VAN Hoylandt, et al.
Gynecological Surgery|May 27, 2016
Laparoscopic versus robotic-assisted sacrocolpopexy for pelvic organ prolapse: a systematic reviewGeertje Callewaert, Jan Bosteels, Susanne Housmans, et al.
Gynecologic Oncology|June 16, 2004
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcomaFrederic Amant, Katrien Schurmans, Edwin Steenkiste, et al.
Gynecologic Oncology|March 14, 2018
Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortiumJohanna M Gostner, Eva Obermayr, Ioana E Braicu, et al.
Pageof 58

Showing results (211-220 of 578) with videos related to

Sort By:
Pageof 58
Anticancer Research|December 11, 2013
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trialAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
Pharmaceutics|April 23, 2022
Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse ModelRoxanne Wouters, Sara Westrøm, Ann Vankerckhoven, et al.
Cancers|March 28, 2024
TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing MiceYani Berckmans, Ann Vankerckhoven, Aarushi Audhut Caro, et al.
Gynecologic Oncology|June 24, 2005
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancerFrederic Amant, Isabelle Cadron, Luca Fuso, et al.
Gynecologic Oncology|January 31, 2013
A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal massJeroen Kaijser, Toon Van Gorp, Kirsten Van Hoorde, et al.
Gynecologic Oncology|May 1, 2015
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancerScott McMeekin, Don Dizon, James Barter, et al.
Anticancer Research|October 30, 2016
The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian CancerEva Vindevogel, Thaïs Baert, Anaïs VAN Hoylandt, et al.
Gynecological Surgery|May 27, 2016
Laparoscopic versus robotic-assisted sacrocolpopexy for pelvic organ prolapse: a systematic reviewGeertje Callewaert, Jan Bosteels, Susanne Housmans, et al.
Gynecologic Oncology|June 16, 2004
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcomaFrederic Amant, Katrien Schurmans, Edwin Steenkiste, et al.
Gynecologic Oncology|March 14, 2018
Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortiumJohanna M Gostner, Eva Obermayr, Ioana E Braicu, et al.
Pageof 58